Vanguard Capital Wealth Advisors acquired a new stake in shares of Omeros Co. (NASDAQ:OMER) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 21,354 shares of the biopharmaceutical company’s stock, valued at approximately $415,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Interstate Bank bought a new stake in shares of Omeros during the third quarter valued at approximately $108,000. C M Bidwell & Associates Ltd. bought a new stake in Omeros in the fourth quarter valued at $106,000. Cypress Capital Group bought a new stake in Omeros in the fourth quarter valued at $194,000. Cambridge Investment Research Advisors Inc. bought a new stake in Omeros in the third quarter valued at $256,000. Finally, SG Americas Securities LLC grew its position in Omeros by 138.9% in the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock valued at $263,000 after acquiring an additional 7,067 shares during the period. Institutional investors and hedge funds own 48.56% of the company’s stock.
Omeros stock opened at $11.01 on Monday. Omeros Co. has a one year low of $8.36 and a one year high of $27.09. The company has a quick ratio of 4.10, a current ratio of 4.12 and a debt-to-equity ratio of -29.93. The firm has a market capitalization of $536.94, a PE ratio of -9.50 and a beta of 3.57.
Omeros (NASDAQ:OMER) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The business had revenue of $13.76 million during the quarter, compared to analysts’ expectations of $21.94 million. During the same quarter last year, the firm earned ($0.45) earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. equities research analysts expect that Omeros Co. will post -0.76 EPS for the current fiscal year.
A number of analysts have weighed in on OMER shares. Bank of America upped their price target on Omeros from $2.44 to $4.00 in a research report on Wednesday, February 14th. HC Wainwright set a $30.00 price target on Omeros and gave the company a “buy” rating in a research report on Tuesday, January 23rd. Finally, Maxim Group set a $24.00 price target on Omeros and gave the company a “buy” rating in a research report on Monday, January 22nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Omeros has an average rating of “Hold” and a consensus price target of $28.75.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/19/vanguard-capital-wealth-advisors-acquires-new-stake-in-omeros-co-omer.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.